We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
Cap. Flow
+$24.2M
Cap. Flow %
3.06%
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$35.2M
2
UTHR icon
United Therapeutics
UTHR
+$14.5M
3
ABVX
Abivax
ABVX
+$9.93M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$9.38M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.02M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$10.4M
2
TERN
Terns Pharmaceuticals
TERN
+$9.58M
3
TGTX icon
TG Therapeutics
TGTX
+$8.47M
4
INCY icon
Incyte
INCY
+$7.74M
5
JNJ icon
Johnson & Johnson
JNJ
+$7.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 66.57%
2 Healthcare 33.4%
3 Consumer Discretionary 0.02%
4 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
51
CALL
Arcus Biosciences
RCUS
$3.78B
$3.82M 0.48%
+124,000
New +$3.06M
UNCY icon
52
CALL
Unicycive Therapeutics
UNCY
$144M
$3.72M 0.47%
+792,600
New +$5.85M
ZYME icon
53
Zymeworks
ZYME
$2.09B
$3.72M 0.47%
142,132
– –
AMGN icon
54
CALL
Amgen
AMGN
$236B
$3.62M 0.46%
+10,000
New +$3.42M
BIOA
55
BioAge Labs
BIOA
$440M
$3.59M 0.45%
146,334
+86,334
+144% +$1.56M
TSHA icon
56
Taysha Gene Therapies
TSHA
$1.82B
$3.56M 0.45%
+522,619
New +$3.09M
NTLA icon
57
CALL
Intellia Therapeutics
NTLA
$1.79B
$3.38M 0.43%
200,000
– –
CLDX icon
58
PUT
Celldex Therapeutics
CLDX
$3.12B
$3.2M 0.4%
+86,000
New +$2.78M
PCVX icon
59
CALL
Vaxcyte
PCVX
$9.1B
$3.09M 0.39%
53,100
– –
NRIX icon
60
Nurix Therapeutics
NRIX
$2.71B
$2.95M 0.37%
+121,539
New +$2.07M
SMMT icon
61
PUT
Summit Therapeutics
SMMT
$14B
$2.91M 0.37%
+200,000
New +$3.55M
PCVX icon
62
PUT
Vaxcyte
PCVX
$9.1B
$2.84M 0.36%
+48,900
New +$2.66M
CRBP icon
63
Corbus Pharmaceuticals
CRBP
$214M
$2.83M 0.36%
301,264
-138,693
-32% -$1.31M
INDV icon
64
Indivior Pharmaceuticals
INDV
$4.12B
$2.77M 0.35%
67,512
-3,864
-5% -$140K
IVA
65
Inventiva
IVA
$1.13B
$2.73M 0.34%
740,786
+388,387
+110% +$1.87M
NVO
66
PUT
Novo Nordisk
NVO
$206B
$2.68M 0.34%
55,900
– –
ORKA
67
Oruka Therapeutics
ORKA
$6.13B
$2.65M 0.33%
+27,799
New +$1.85M
PCVX icon
68
Vaxcyte
PCVX
$9.1B
$2.62M 0.33%
45,071
+20,000
+80% +$1.09M
CYTK icon
69
PUT
Cytokinetics
CYTK
$10.1B
$2.56M 0.32%
30,000
-170,000
-85% -$12.2M
RLMD icon
70
Relmada Therapeutics
RLMD
$473M
$2.5M 0.32%
361,367
+160,525
+80% +$1.12M
VERA icon
71
Vera Therapeutics
VERA
$2.59B
$2.47M 0.31%
+57,608
New +$2.15M
VERA icon
72
PUT
Vera Therapeutics
VERA
$2.59B
$2.15M 0.27%
+50,000
New +$1.86M
CELC icon
73
CALL
Celcuity
CELC
$4.68B
$2.09M 0.26%
20,000
+2,300
+13% +$265K
ANNX icon
74
CALL
Annexon
ANNX
$923M
$2.02M 0.25%
353,200
– –
SEPN
75
PUT
Septerna Inc
SEPN
$1.72B
$2M 0.25%
+59,700
New +$1.69M
1 2
3
4 5

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.

By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.

  • Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
  • Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
  • Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
  • Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
  • Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
  • Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
  • Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.